VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S.

First-in-class condensate-modulating small molecule Development Candidate targeting pathogenic TDP-43 condensates.Restores global TDP-43 splicing ...

NRG5051 is a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial permeability transition pore (mPTP), acting through a novel undisclosed ...

Health Canada has cleared the way for ALS patients in that nation to join the ongoing ALSTARS U.S. trial testing therapy ...

Historically, people with amyotrophic lateral sclerosis (ALS) experience a relentless decline in neurological function that eventually robs them of the ability to move, speak, eat or breathe. Now, ...

A pharmaceutical company based in New Jersey that’s known for its FDA-approved treatment for ALS is set to be acquired for $2 ...

Some people with SOD1-ALS experienced improvements in physical function and muscle strength after three years on Qalsody, an ...

According to the CDC, around 5,000 people in the U.S. are diagnosed with ALS every year. There is no cure for this neurological illness. Although anglers across the Northland were taking advantage of ...

Six newly Certified Centers join the organization's network of clinics and expand access to multidisciplinary care and research for people living with ALS. ALS, often called Lou Gehrig's disease, is a ...